Friday, 24 November 2017
Latest news
Main » Teva Pharmaceutical Industries Limited (TEVA) Receives Hold Rating from Oppenheimer Holdings, Inc

Teva Pharmaceutical Industries Limited (TEVA) Receives Hold Rating from Oppenheimer Holdings, Inc

14 November 2017

As per Tuesday, January 31, the company rating was upgraded by Bank of America. The rating was maintained by Panmure Gordon on Thursday, November 3 with "Buy". This epic surge brought the stock's 14-day Relative Strength Index (RSI) to a lofty 74 at last Friday's close, indicating the equity was overbought and a short-term pullback was likely in the cards. Teva Pharmaceutical Industries Limited has a consensus rating of Hold and a consensus price target of $22.26.

Last week, Calcalist reported that Fitch Ratings Inc. downgraded Teva's rating from BBB to BB, with a negative outlook, effectively moving Teva to non-investment grade.

Teva Pharmaceutical has a 52 week low of $13.26 and a 52 week high of $44.12 The company's market cap is now $0. The firm earned "Buy" rating on Tuesday, March 15 by Cantor Fitzgerald. On Tuesday, February 21 the stock rating was downgraded by Jefferies to "Hold". Seven research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Therefore 26% are positive. Teva Pharmaceutical Industries Limited has a 52 week low of $10.85 and a 52 week high of $41.19.

More news: China, Asean agree to 10-year China Sea protection pact

Short interest, or the number of a stock's tradable shares now being shorted, is another metric investors use to get a pulse on sentiment. The firm earned "Neutral" rating on Wednesday, August 16 by Citigroup. Susquehanna Bancshares Inc reduced their price objective on Teva Pharmaceutical Industries Limited from $20.00 to $14.00 and set a "positive" rating for the company in a research note on Monday, November 6th. Mizuho maintained the shares of TEVA in report on Wednesday, October 4 with "Hold" rating. Credit Suisse downgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Tuesday, September 5 to "Sell" rating. As per Friday, August 4, the company rating was downgraded by RBC Capital Markets. This works out to a net decrease in ownership of 23.11 million shares, and suggests that institutions are feeling bearish about the stock. The firm has "Hold" rating given on Thursday, July 13 by Maxim Group. On Friday, February 24 the stock rating was maintained by Barclays Capital with "Equal Weight". The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned "Buy" rating by Standpoint Research on Monday, July 27.

Yesterday Teva Pharmaceutical (NYSE:TEVA) traded 2.03% higher at $11.66.

Let's have a look at some of the important valuation ratios of the Teva Pharmaceutical Industries Limited (TEVA). It has underperformed by 58.40% the S&P500. The legal version of this story can be read at https://weekherald.com/2017/11/13/teva-pharmaceutical-industries-limited-teva-lowered-to-market-perform-at-wells-fargo-company.html. The firm has a market cap of $11,968.48, a price-to-earnings ratio of 2.72 and a beta of 0.52. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. It now has negative earnings. The Company operates through two segments: Generic medicines and Specialty medicines. The Advantus Capital Management Inc holds 62,237 shares with $2.06M value, down from 174,781 last quarter. Among active positions in the latest quarter, 256 holders increased their positions by a total of 67.28 million shares, 367 holders decreased the positions by a total of 90.38 million shares, and 92 holders held their positions.

More news: Man Utd to cash in on Luke Shaw

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down $0.04 on Thursday, reaching $11.74. CIBC Asset Management Inc boosted its position in shares of Teva Pharmaceutical Industries Limited by 0.3% in the 2nd quarter.

Zotefoams plc is a United Kingdom-based cellular material technology company. It has a 9.95 P/E ratio. The Company's divisions include Polyolefins, High-Performance Products and MuCell Extrusion LLC (MEL). J C Penney Company Inc (NYSE:JCP) has declined 40.00% since November 13, 2016 and is downtrending. It has underperformed by 15.74% the S&P500.

More news: JC Penney Company, Inc. Holding Company (NYSE:JCP) stock to follow